LIB de­tails Ph3 PC­SK9 in­hibitor da­ta; Eye­n­ovia seeks 's­trate­gic al­ter­na­tives'

Plus, news about In­ozyme and Sen­so­ri­on:

LIB Ther­a­peu­tics touts pos­i­tive Phase 3 cho­les­terol re­sults: The com­pa­ny’s third-gen­er­a­tion PC­SK9 in­hibitor, lero­dal­cibep, achieved a 56%

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER